BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014; 20(35): 12581-12587 [PMID: 25253961 DOI: 10.3748/wjg.v20.i35.12581]
URL: https://www.wjgnet.com/1948-5182/full/v20/i35/12581.htm
Number Citing Articles
1
Ming-Han Hsieh, Tzu-Yu Kao, Ting-Hui Hsieh, Chun-Chi Kao, Cheng-Yuan Peng, Hsueh-Chou Lai, Po-Heng Chuang, Jung-Ta Kao, Ming-Lung Yu. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenibPLOS ONE 2020; 15(12): e0244293 doi: 10.1371/journal.pone.0244293
2
Fatemeh Shafie, Fatemeh Nabavizadeh, Mehdi Shafie Ardestani, Mahshid Panahi, Soheila Adeli, Hedayat Samandari, Ghorbangol Ashabi. Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated ratsCanadian Journal of Physiology and Pharmacology 2019; 97(8): 691 doi: 10.1139/cjpp-2019-0141
3
Shaoming Song, Mingzhen Bai, Xiaofei Li, Shiyi Gong, Wenwen Yang, Caining Lei, Hongwei Tian, Moubo Si, Xiangyong Hao, Tiankang Guo. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinomaExpert Review of Molecular Diagnostics 2022; 22(3): 361 doi: 10.1080/14737159.2022.2049248
4
Wen-Tsan Chang, Sheng-Nan Lu, Kung-Ming Rau, Ching-Shan Huang, King-Teh Lee. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patientsThe Kaohsiung Journal of Medical Sciences 2018; 34(7): 391 doi: 10.1016/j.kjms.2018.03.006
5
R. Diaz-Beveridge, G. Bruixola, D. Lorente, J. Caballero, E. Rodrigo, Á. Segura, D. Akhoundova, A. Giménez, J. Aparicio. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenibClinical and Translational Oncology 2018; 20(3): 322 doi: 10.1007/s12094-017-1720-4
6
Brian C. Grieb, Laura W. Goff, Lipika Goyal, Crystal S. Denlinger. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future FrontiersAmerican Society of Clinical Oncology Educational Book 2019; (39): 248 doi: 10.1200/EDBK_237555
7
Suguru Hirose, Kazunori Ishige, Masamichi Yamaura, Tsuneo Mizui, Yoshiki Komatsu, Masaomi Nagase, Masashi Sato, Junji Hattori, Masato Endo, Naoyuki Hasegawa, Kuniaki Fukuda, Ichinosuke Hyodo. A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapyClinical Journal of Gastroenterology 2020; 13(5): 902 doi: 10.1007/s12328-020-01154-z
8
Omar Abdel-Rahman, Angela Lamarca. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survivalExpert Review of Gastroenterology & Hepatology 2017; 11(1): 75 doi: 10.1080/17474124.2017.1264874
9
Ping Wang, Gang Tan, Mingxin Zhu, Weidong Li, Bo Zhai, Xueying Sun. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysisExpert Review of Gastroenterology & Hepatology 2018; 12(1): 1 doi: 10.1080/17474124.2017.1373018
10
Ming‐Lun Yeh, Chung‐Feng Huang, Ching‐I Huang, Ming‐Yen Hsieh, Nei‐Jen Hou, I‐Hung Lin, Po‐Cheng Liang, Yi‐Shan Tsai, Meng‐Hsuan Hsieh, Zu‐Yau Lin, Shinn‐Chern Chen, Chia‐Yen Dai, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatmentThe Kaohsiung Journal of Medical Sciences 2019; 35(10): 624 doi: 10.1002/kjm2.12105
11
Tom M. Ganten, Rudolf E. Stauber, Eckardt Schott, Peter Malfertheiner, Robert Buder, Peter R. Galle, Thomas Göhler, Matthias Walther, Ronald Koschny, Guido Gerken. Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT StudyClinical Cancer Research 2017; 23(19): 5720 doi: 10.1158/1078-0432.CCR-16-0919
12
Álvaro Díaz-González, Marco Sanduzzi-Zamparelli, Víctor Sapena, Ferran Torres, Neus LLarch, Gemma Iserte, Alejandro Forner, Leonardo da Fonseca, José Ríos, Jordi Bruix, María Reig. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenibAlimentary Pharmacology & Therapeutics 2019; 49(5): 482 doi: 10.1111/apt.15088
13
Lei Liu, Enxin Wang, Lin Li, Dongyu Chen, Kun Peng, Mengmeng Wang, Guohong Han. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus SorafenibCanadian Journal of Gastroenterology and Hepatology 2019; 2019: 1 doi: 10.1155/2019/2576349
14
Regiane S. S. M. Alencar, Luciana Kikuchi, Cláudia M. Tani, Aline L. Chagas, Cinira C. Camargo, Túlio E. F. Pfiffer, Paulo M. G. Hoff, Flair J. Carrilho. Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on SurvivalJournal of Cancer Therapy 2016; 7(04): 275 doi: 10.4236/jct.2016.74029
15
Fernanda Branco, Regiane S.M. Alencar, Fernanda Volt, Giovana Sartori, Andressa Dode, Luciana Kikuchi, Claudia M. Tani, Aline L. Chagas, Tulio Pfiffer, Paulo Hoff, Flair J. Carrilho, Angelo Alves de Mattos. The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with SorafenibAnnals of Hepatology 2017; 16(2): 263 doi: 10.5604/16652681.1231587
16
Ming-Chin Yu, Tsung-Han Wu, Chao-Wei Lee, Yun-Shien Lee, Jang-Hau Lian, Chia-Lung Tsai, Sen-Yung Hsieh, Chi-Neu Tsai. Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinomaBiomedical Journal 2021; 44(6): S73 doi: 10.1016/j.bj.2020.07.001
17
Christoph Zielinski, Istvan Lang, Semir Beslija, Zsuzsanna Kahan, Moshe J Inbar, Salomon M Stemmer, Rodica Anghel, Damir Vrbanec, Diethelm Messinger, Thomas Brodowicz. Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancerBritish Journal of Cancer 2016; 114(2): 163 doi: 10.1038/bjc.2015.419
18
Kazuo Kobayashi, Kazuyoshi Kawakami, Takashi Yokokawa, Takeshi Aoyama, Kenichi Suzuki, Takeru Wakatsuki, Mitsukuni Suenaga, Hitoshi Sato, Erika Sugiyama, Kensei Yamaguchi, Toshihiro Hama. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal CancerOncology 2019; 96(4): 200 doi: 10.1159/000495989
19
Carol Mansfield, Sandy Srinivas, Connie Chen, A. Brett Hauber, Subramanian Hariharan, Ewa Matczak, Rickard Sandin. The effect of information on preferences for treatments of metastatic renal cell carcinomaCurrent Medical Research and Opinion 2016; 32(11): 1827 doi: 10.1080/03007995.2016.1211521
20
Anne Hulin, Jeanick Stocco, Mohamed Bouattour. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular CarcinomaClinical Pharmacokinetics 2019; 58(8): 983 doi: 10.1007/s40262-019-00740-w
21
Giovan Giuseppe Di Costanzo, Andrea Casadei Gardini, Giorgia Marisi, Francesco Giuseppe Foschi, Mario Scartozzi, Rocco Granata, Luca Faloppi, Stefano Cascinu, Nicola Silvestris, Oronzo Brunetti, Vincenzo Ostilio Palmieri, Giorgio Ercolani, Raffaella Tortora. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular CarcinomaTargeted Oncology 2017; 12(6): 795 doi: 10.1007/s11523-017-0522-5
22
Carina Hage, Sabine Hoves, Léanne Strauss, Stefan Bissinger, Ylva Prinz, Thomas Pöschinger, Fabian Kiessling, Carola H. Ries. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular CarcinomaHepatology 2019; 70(4): 1280 doi: 10.1002/hep.30666
23
Vicente Escudero-Vilaplana, Jose Luis Revuelta-Herrero, Roberto Collado-Borrell, Belen Marzal-Alfaro, Alvaro Gimenez-Manzorro, Ana Herranz-Alonso, María Sanjurjo-Saez. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practiceExpert Opinion on Drug Safety 2019; 18(9): 861 doi: 10.1080/14740338.2019.1641197
24
Alessandro Granito, Sara Marinelli, Giulia Negrini, Saverio Menetti, Francesca Benevento, Luigi Bolondi. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenibTherapeutic Advances in Gastroenterology 2016; 9(2): 240 doi: 10.1177/1756283X15618129